EVO News and Press, Evotec SE From 10/25/22

German life sciences company Evotec SE ( NASDAQ: EVO ) ( OTCPK:EVOTF ) gained ~6% on Tuesday after announcing a partnership with German university Hannover Medical School to develop a molecular database to understand autoimmune disorders Sjögren's syndrome and sys...

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN'S SYNDROME ("SJS") AND SYSTEMIC LUPUS ERYTHEMATOSUS ("SLE") HANNOVER MEDICAL SCHOOL ("MHH") WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECH...

Evotec ( NASDAQ: EVO ) on Tuesday said that it launched the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World in Berlin. Evotec is now making PanHunter available to collaborators and partners as a software-as-a-service (SaaS...

PANHUNTER EMPOWERS ANY SCIENTIST TO ACCESS AND ANALYSE DEEP BIOLOGICAL AND CLINICAL DATA INCLUDING IN PARTICULAR HUGE PANOMICS DATA SETS PANHUNTER ACCELERATES THE R&D PROCESS AND IMPROVES SUCCESS RATES HAMBURG, GERMANY / ACCESSWIRE / October 18, 2022 / Evotec SE (Frankfurt Stock Exch...

Toronto Innovation Acceleration Partners (TIAP) and Evotec ( NASDAQ: EVO ) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen ( NASDAQ: AMGN ) as a strategic partner. The expansion goes along with a combined inv...

AMGEN TO JOIN LAB150 TO BUILD CANADA'S NEXT GENERATION OF LIFE SCIENCE COMPANIES HAMBURG, GERMANY and TORONTO, ON / ACCESSWIRE / October 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Toronto Innovation Acceleration Partners ("TIAP"...

Amgen to Join LAB150 to Build Canada’s Next Generation of Life Science Companies Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the tw...

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) is collaborating with Adapsyn Bioscience to gain access to novel drug-like small molecules from microorganisms. Financial details were not disclosed. Under the agreement, Evotec will have the opportunity to evalu...

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-ba...

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANT / ACCESSWIRE / September 20, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDA...